Essex Investment Management Co. LLC Has $598,000 Holdings in Adaptimmune Therapeutics PLC (ADAP)

Essex Investment Management Co. LLC trimmed its holdings in shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) by 62.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 72,996 shares of the biotechnology company’s stock after selling 119,049 shares during the period. Essex Investment Management Co. LLC owned about 0.08% of Adaptimmune Therapeutics PLC worth $598,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. KCG Holdings Inc. purchased a new stake in Adaptimmune Therapeutics PLC during the first quarter valued at about $133,000. OxFORD Asset Management LLP purchased a new stake in Adaptimmune Therapeutics PLC during the second quarter valued at about $156,000. Paloma Partners Management Co purchased a new stake in Adaptimmune Therapeutics PLC during the first quarter valued at about $165,000. Virtu KCG Holdings LLC raised its stake in shares of Adaptimmune Therapeutics PLC by 108.0% during the second quarter. Virtu KCG Holdings LLC now owns 50,279 shares of the biotechnology company’s stock valued at $226,000 after acquiring an additional 26,105 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new position in shares of Adaptimmune Therapeutics PLC during the second quarter valued at about $242,000. Institutional investors and hedge funds own 68.30% of the company’s stock.

Several equities analysts have recently commented on ADAP shares. BidaskClub raised shares of Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a research note on Friday, August 25th. Leerink Swann reaffirmed an “outperform” rating and set a $15.00 price objective on shares of Adaptimmune Therapeutics PLC in a research note on Friday, September 8th. Zacks Investment Research raised shares of Adaptimmune Therapeutics PLC from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a research note on Wednesday, July 12th. ValuEngine raised shares of Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 20th. Finally, SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $10.00 price objective on shares of Adaptimmune Therapeutics PLC in a research note on Thursday, October 12th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $11.58.

TRADEMARK VIOLATION WARNING: “Essex Investment Management Co. LLC Has $598,000 Holdings in Adaptimmune Therapeutics PLC (ADAP)” was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.com-unik.info/2017/11/05/essex-investment-management-co-llc-has-598000-holdings-in-adaptimmune-therapeutics-plc-adap.html.

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) opened at $8.17 on Friday.

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last issued its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.24) EPS for the quarter, meeting the consensus estimate of ($0.24). The firm had revenue of $3.52 million during the quarter, compared to the consensus estimate of $5.43 million. Adaptimmune Therapeutics PLC had a negative net margin of 138.46% and a negative return on equity of 28.95%. sell-side analysts forecast that Adaptimmune Therapeutics PLC will post -0.82 earnings per share for the current year.

Adaptimmune Therapeutics PLC Company Profile

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Want to see what other hedge funds are holding ADAP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adaptimmune Therapeutics PLC (NASDAQ:ADAP).

Institutional Ownership by Quarter for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)

What are top analysts saying about Adaptimmune Therapeutics PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Adaptimmune Therapeutics PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit